Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177.
PMID: 38301682
Refractory dermatomyositis responsive to anifrolumab.
Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep. 2024 Jan; 43:27-29.
PMID: 38162409
A single center pilot study: assessing resident needs and faculty perceptions to improve training in rheumatology.
A single center pilot study: assessing resident needs and faculty perceptions to improve training in rheumatology. BMC Med Educ. 2023 May 19; 23(1):351.
PMID: 37208739
Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis.
Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis. J Clin Invest. 2022 07 01; 132(13).
PMID: 35608910
Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejection.
Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejection. Nat Commun. 2021 07 16; 12(1):4372.
PMID: 34272370
Cellular aspects of the pathogenesis of lupus nephritis.
Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021 03 01; 33(2):197-204.
PMID: 33394604
Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis.
Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus. 2020 May; 29(6):569-577.
PMID: 32216516
Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.
Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. Arthritis Rheumatol. 2016 11; 68(11):2740-2751.
PMID: 27159593
Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations.
Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J Autoimmun. 2015 Jun; 60:51-58.
PMID: 25921064
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis.
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 2014 Dec; 66(12):3359-70.
PMID: 25306868